Successfull device feasibility studies with sterna biologicals asthma drug candidates SB010 enables select of optimal nebulizers for late-stage development and commercialization
Marburg, Germany, September 05, 2018
- Feasibility studies show excellent data with SB010 across a selection of high efficiency hand-held nebulizers
- Company well positioned to advance SB010 into late-stage clinical development
Sterna biologicals GmbH & Co. KG (“sterna”), an innovative clinical-stage immunology company developing novel treatments for chronic inflammatory diseases, announced today that the Company has successfully completed in vitro device feasibility studies with its asthma drug candidate, SB010. These studies support the selection of the most efficient and user-friendly device options for late-stage development and commercialization of SB010.